Literature DB >> 9088056

Human immunodeficiency virus (HIV) infection and quality of life: the potential impact of Axis I psychiatric disorders in a sample of 95 HIV seropositive men.

W C Holmes1, B Bix, M Meritz, J Turner, C Hutelmyer.   

Abstract

OBJECTIVE: The purpose of this study is to assess whether Axis I psychiatric disorders exert effects on function and well-being independent of human immunodeficiency virus (HIV)-related disease progression.
METHODS: A convenience sample of 95 HIV seropositive individuals completed the Medical Outcomes Study Short Form Health Survey (SF-20). The Standardized Clinical Interview for DSM-III-R (SCID-NP-HIV) was used to screen subjects for Axis I psychiatric disorders in the previous 6 months. HIV-related disease severity was defined for each subject using the 1993 revised Centers for Disease Control (CDC) Classification System.
RESULTS: Thirty-seven (39%) subjects had asymptomatic HIV disease and 58 (61%) had symptomatic disease. Thirty-three (35%) subjects had Axis I disorders in the previous 6 months. After controlling for HIV-related disease severity, psychiatric disorders were independently associated with substantive decrements in the mental health and health perceptions dimension scores (beta-coefficients were approximately -18.0 for both dimensions; p < or = 0.01). Axis I disorders were also associated with decrements in the social functioning dimension at a p value that approached significance (p = 0.04).
CONCLUSIONS: In HIV seropositive individuals, the presence of an Axis I psychiatric disorder in the previous 6 months is associated with diminished scores in multiple areas of functioning and well-being, independent of HIV-related disease progression. Axis I disorders, therefore, appear to impact quality of life. These findings, in part, suggest that the SF-20 (the mental health subscale, in particular) may have utility as a screening tool for the presence of a recent Axis I diagnosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9088056     DOI: 10.1097/00006842-199703000-00011

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  8 in total

1.  Use of Medicaid data to explore community characteristics associated with HIV prevalence among beneficiaries with schizophrenia.

Authors:  James Walkup; Ayse Akincigil; Donald R Hoover; Michele J Siegel; Shahla Amin; Stephen Crystal
Journal:  Public Health Rep       Date:  2011 Sep-Oct       Impact factor: 2.792

2.  The role of illness, resources, appraisal, and coping strategies in adjustment to HIV/AIDS: the direct and buffering effects.

Authors:  K I Pakenham; M Rinaldis
Journal:  J Behav Med       Date:  2001-06

3.  Antidepressant treatment and health services utilization among HIV-infected medicaid patients diagnosed with depression.

Authors:  U Sambamoorthi; J Walkup; M Olfson; S Crystal
Journal:  J Gen Intern Med       Date:  2000-05       Impact factor: 5.128

Review 4.  Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS.

Authors:  A W Wu; R D Hays; S Kelly; F Malitz; S A Bozzette
Journal:  Qual Life Res       Date:  1997-08       Impact factor: 4.147

5.  Lifetime suicide attempt history, quality of life, and objective functioning among HIV/AIDS patients with alcohol and illicit substance use disorders.

Authors:  Kimberly N Walter; Nancy M Petry
Journal:  Int J STD AIDS       Date:  2015-05-06       Impact factor: 1.359

6.  The influence of psychological variables on health-related quality of life among HIV-positive individuals with a history of intravenous drug use.

Authors:  Christina Psaros; Conall O'Cleirigh; Jacqueline R Bullis; Sarah M Markowitz; Steven A Safren
Journal:  J Psychoactive Drugs       Date:  2013 Sep-Oct

7.  Quality of life in HIV/AIDS.

Authors:  K H Basavaraj; M A Navya; R Rashmi
Journal:  Indian J Sex Transm Dis AIDS       Date:  2010-07

8.  The relationship of CSF and plasma cytokine levels in HIV infected patients with neurocognitive impairment.

Authors:  Lin Yuan; An Liu; Luxin Qiao; Bo Sheng; Meng Xu; Wei Li; Dexi Chen
Journal:  Biomed Res Int       Date:  2015-03-03       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.